Green Valley’s Oligomannate Approved for Alzheimer’s Disease Treatment in China Representing the First AD Approval in Decades

Green Valley’s Oligomannate Approved for Alzheimer’s Disease Treatment in China Representing the First AD Approval in Decades

Shanghai China’s Green Valley Pharmaceuticals (Green Valley) received approval from the China National Medical Products Administration (NMPA) for their Oligomannate (GV-971) as a new drug for the treatment of mild to moderate Alzheimer’s disease (AD) and improving...
Washington University Taylor Family Institute for Innovative Psychiatric Research-Originated Drug in Clinical Trials for Major Depression

Washington University Taylor Family Institute for Innovative Psychiatric Research-Originated Drug in Clinical Trials for Major Depression

33% of 14 million American’s suffering from clinical depression get no relief from today’s approved antidepressant drugs.  A new treatment approach involving neurosteroids is on the horizon however that may be more effective. The strategy of using neurosteroids was...

Pin It on Pinterest